Boryung (003850.KS) Stock Price
Boryung Price
Over the last 19 years Boryung grew revenue by 9.5% annually, reaching 1.02 T KRW. Earnings per share have grown at 20.4% per year over the last 19 years. For Boryung, the net margin of 6.3% is broadly stable versus 6.9% a few years ago. At today's price the dividend yield works out to roughly 1.90%. The payout ratio is around 10% of earnings. The dividend has grown at 14.6% per year over the past 19 years. The consensus 12-month price target for Boryung is 12,240.00 KRW, about 45.4% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Boryung stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Boryung business model & stock analysis
Frequently asked questions about Boryung
The business model of Boryung Corp is focused on pharmaceuticals and healthcare products. Boryung Corp operates as a global biopharmaceutical company, dedicated to developing, manufacturing, and distributing high-quality medications and healthcare solutions. With a strong emphasis on research and development, Boryung Corp strives to discover innovative drugs and treatments to improve the quality of life for patients worldwide. By leveraging its expertise and advanced technologies, Boryung Corp aims to address various medical needs, ranging from chronic diseases to infectious conditions, ultimately contributing to the overall well-being of individuals and communities.
Boryung Corp is primarily active in the pharmaceutical industry.
Boryung Corp faces tough competition from several major players in the market. Some of its main competitors include multinational pharmaceutical companies like Pfizer, Merck, and Novartis. These companies, along with others in the industry, vie for market share and strive to develop innovative pharmaceutical products and expand their global presence. Boryung Corp competes with these well-established players by leveraging its expertise in research and development, focusing on product differentiation, and maintaining strong customer relationships.
Boryung Corp, established in 1963, is a renowned South Korean pharmaceutical company. With a strong focus on research and development, Boryung Corp has grown into a global player in the healthcare industry. The company's diverse portfolio includes prescription drugs, over-the-counter medications, and healthcare products. Boryung Corp has achieved significant milestones in the treatment of various diseases, providing innovative solutions to improve patient outcomes. Through strategic collaborations and investments in cutting-edge technology, Boryung Corp continues to expand its presence in both domestic and international markets. With a rich history and a commitment to advancing healthcare, Boryung Corp remains a trusted name in the pharmaceutical sector.
Boryung Corp has achieved several significant milestones throughout its history. One of the notable achievements includes the development and commercialization of innovative pharmaceutical products. The company has also established a strong presence in the global market by expanding its business operations and collaborations with international partners. Boryung Corp has consistently focused on research and development, leading to breakthroughs and advancements in the healthcare industry. Additionally, the company has been recognized for its commitment to high-quality products and has received various prestigious awards and certifications. Overall, Boryung Corp has demonstrated its dedication to innovation, global growth, and excellence in the pharmaceutical sector.
Boryung Corp is primarily present in South Korea.
Boryung Corp represents a strong set of values and corporate philosophy. The company is dedicated to innovation, excellence, and ethical business practices. With a focus on customer satisfaction, Boryung Corp strives to provide high-quality products and services that meet the diverse needs of its consumers. The company also values sustainability and social responsibility, aiming to make a positive impact on the community and the environment. Boryung Corp's commitment to continuous improvement and proactive strategies has enabled it to establish a reputable presence in the market. Overall, Boryung Corp's values and corporate philosophy are centered around delivering value, fostering growth, and prioritizing the well-being of its stakeholders.
Analysts currently set an average price target of 12,240.00 KRW for the Boryung stock (median: 12,240.00 KRW), implying +45.4 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Boryung stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Boryung to generate revenue of 1.06 T KRW and earnings per share of 1,258.07 KRW.
Converted at the current exchange rate, the Boryung share trades at 5.64 EUR (8,420.00 KRW).
The Boryung share (003850.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (003850.KS).
Boryung Corporation is a Korean company that was founded in 1963 and has been active in various industries since then. The company is headquartered in Seoul and operates in the healthcare, chemical, and biotechnology sectors. In the healthcare sector, Boryung Corp is one of the leading manufacturers of pharmaceuticals in the Korean market. The company specializes in the development and manufacturing of drugs for the treatment of serious diseases such as cancer, diabetes, and cardiovascular diseases. Some of Boryung Corp's most well-known products include the antiviral agent Arvirargen, used in the treatment of influenza, and the cardiological preparation Nitomel, used in the treatment of heart failure. In the chemical sector, Boryung Corp is involved in the production of petrochemical products such as refinery products and polymeric materials. The company also operates a production facility for plastic parts and plastic films, which are used in various industries such as automotive, packaging, and electronics. Boryung Corp is also heavily involved in the biotechnology sector and is developing therapeutic antibodies and immuno-oncological therapies to treat various types of cancer. The company has an exclusive licensing agreement with US-based company OncoMed Pharmaceuticals to enhance the development and commercialization of cancer drugs. An important pillar of Boryung Corp's business model is research and development. The company invests approximately 10% of its revenue annually in research and has its own research facility specializing in biotechnology. In collaboration with other companies, universities, and research institutions in Korea and worldwide, Boryung Corp has demonstrated its ability to develop innovative products and solutions that transform the market. Another important aspect of Boryung Corp's business model is its globally-oriented strategy. The company has a strong presence in the Korean market, but is also expanding into new markets worldwide. Through collaborations with other companies and local trade partners, Boryung Corp has built a strong international presence and operates in over 50 countries. Overall, Boryung Corp's business model is focused on developing and producing innovative solutions in various industries. The company specializes in the manufacturing of high-quality products and heavily invests in research and development to grow in new markets. With its global orientation and wide range of products and services, Boryung Corp is an important player in various industries and a company that is focused on its continuous growth.
The expected revenue of Boryung is 1.06 T KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Boryung is 52.89 B KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Boryung is currently 6.69. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Boryung stock.
The price-to-sales ratio (P/S) of Boryung is currently 0.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Boryung stock.
The Eulerpool Quality Score for Boryung is 7/10.
The ISIN of Boryung is KR7003850005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Boryung is 003850.KS. The ticker symbol is used to trade Boryung shares on the stock exchange.
Boryung stock
Boryung Peer Group
Boryung Ticker
Boryung FIGI
All fundamentals and in-depth analysis of Boryung
Our stock analysis for Boryung stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Boryung. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.